Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2022 Jul 27

PMID 35890342

Authors

Neftali Ortega Alarcon

Maddy Jaramillo

Heidi M Mansour

Bo Sun

Affiliations

Soon will be listed here.

Abstract

For decades, vaccines have played a significant role in protecting public and personal health against infectious diseases and proved their great potential in battling cancers as well. This review focused on the current progress of therapeutic subunit vaccines for cancer immunotherapy. Antigens and adjuvants are key components of vaccine formulations. We summarized several classes of tumor antigens and bioinformatic approaches of identification of tumor neoantigens. Pattern recognition receptor (PRR)-targeting adjuvants and their targeted delivery platforms have been extensively discussed. In addition, we emphasized the interplay between multiple adjuvants and their combined delivery for cancer immunotherapy.

Citing Articles

Developing Vaccines in Pancreatic Adenocarcinoma: Trials and Tribulations.

Phan T, Fan D, Melstrom L Curr Oncol. 2024; 31(9):4855-4884.

PMID: 39329989 PMC: 11430674. DOI: 10.3390/curroncol31090361.

Recent Findings on Therapeutic Cancer Vaccines: An Updated Review.

Sheikhlary S, Lopez D, Moghimi S, Sun B Biomolecules. 2024; 14(4).

PMID: 38672519 PMC: 11048403. DOI: 10.3390/biom14040503.

Lipid Nanoparticle-Based Delivery System-A Competing Place for mRNA Vaccines.

Zhang X, Li Y, Zhou Z ACS Omega. 2024; 9(6):6219-6234.

PMID: 38371811 PMC: 10870384. DOI: 10.1021/acsomega.3c08353.

Prostate cancer autoantibodies - applications in diagnosis, prognosis, monitoring disease progression and immunotherapy.

Jayakrishnan R, Schafer C, Tan S Am J Clin Exp Urol. 2023; 11(2):79-102.

PMID: 37168942 PMC: 10165224.

Advances of mRNA vaccine in tumor: a maze of opportunities and challenges.

Yuan Y, Gao F, Chang Y, Zhao Q, He X Biomark Res. 2023; 11(1):6.

PMID: 36650562 PMC: 9845107. DOI: 10.1186/s40364-023-00449-w.

References

Hasegawa K, Noguchi Y, Koizumi F, Uenaka A, Tanaka M, Shimono M . In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope. Clin Cancer Res. 2006; 12(6):1921-7. DOI: 10.1158/1078-0432.CCR-05-1900. View

Agier J, Zelechowska P, Kozlowska E, Brzezinska-Blaszczyk E . Expression of surface and intracellular Toll-like receptors by mature mast cells. Cent Eur J Immunol. 2017; 41(4):333-338. PMC: 5382879. DOI: 10.5114/ceji.2016.65131. View

Dudek A, Yunis C, Harrison L, Kumar S, Hawkinson R, Cooley S . First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin Cancer Res. 2007; 13(23):7119-25. DOI: 10.1158/1078-0432.CCR-07-1443. View

Ayyoub M, Hesdorffer C, Montes M, Merlo A, Speiser D, Rimoldi D . An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR. J Clin Invest. 2004; 113(8):1225-33. PMC: 385406. DOI: 10.1172/JCI20667. View

Harada M, Li Y, Ohnmacht G, Rosenberg S, Robbins P . Melanoma-Reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types. J Immunother. 2001; 24(4):323-33. DOI: 10.1097/00002371-200107000-00008. View

Wang X, Cohen W, Castelli F, Almunia C, Lethe B, Pouvelle-Moratille S . Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family. Cancer Immunol Immunother. 2006; 56(6):807-18. PMC: 11030775. DOI: 10.1007/s00262-006-0230-y. View

Corrales L, Glickman L, McWhirter S, Kanne D, Sivick K, Katibah G . Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015; 11(7):1018-30. PMC: 4440852. DOI: 10.1016/j.celrep.2015.04.031. View

Zorn E, Hercend T . A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur J Immunol. 1999; 29(2):592-601. DOI: 10.1002/(SICI)1521-4141(199902)29:02<592::AID-IMMU592>3.0.CO;2-2. View

Ohue Y, Eikawa S, Okazaki N, Mizote Y, Isobe M, Uenaka A . Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients. Int J Cancer. 2011; 131(5):E649-58. DOI: 10.1002/ijc.27359. View

10.

Kawakami Y, Wang X, Shofuda T, Sumimoto H, Tupesis J, Fitzgerald E . Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes. J Immunol. 2001; 166(4):2871-7. DOI: 10.4049/jimmunol.166.4.2871. View

11.

Kapadia C, Tian S, Perry J, Sailer D, Luft J, DeSimone J . Extending antigen release from particulate vaccines results in enhanced antitumor immune response. J Control Release. 2017; 269:393-404. DOI: 10.1016/j.jconrel.2017.11.020. View

12.

Kawakami Y, Robbins P, Wang X, Tupesis J, Parkhurst M, Kang X . Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol. 1998; 161(12):6985-92. View

13.

Rongcun Y, Salazar-Onfray F, Charo J, Malmberg K, Evrin K, Maes H . Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol. 1999; 163(2):1037-44. View

14.

Labarriere N, Bretaudeau L, Gervois N, Bodinier M, Bougras G, Diez E . Apoptotic body-loaded dendritic cells efficiently cross-prime cytotoxic T lymphocytes specific for NA17-A antigen but not for Melan-A/MART-1 antigen. Int J Cancer. 2002; 101(3):280-6. DOI: 10.1002/ijc.10605. View

15.

Qi X, Lam S, Liu D, Kim D, Ma L, Alleruzzo L . Development of inCVAX, Cancer Vaccine, and Its Immune Response in Mice with Hepatocellular Cancer. J Clin Cell Immunol. 2016; 7(4). PMC: 5027967. DOI: 10.4172/2155-9899.1000438. View

16.

Underhill D . Collaboration between the innate immune receptors dectin-1, TLRs, and Nods. Immunol Rev. 2007; 219:75-87. DOI: 10.1111/j.1600-065X.2007.00548.x. View

17.

Olson B, Frye T, Johnson L, Fong L, Knutson K, Disis M . HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother. 2010; 59(6):943-53. PMC: 3038205. DOI: 10.1007/s00262-010-0820-6. View

18.

Yan M, Himoudi N, Pule M, Sebire N, Poon E, Blair A . Development of cellular immune responses against PAX5, a novel target for cancer immunotherapy. Cancer Res. 2008; 68(19):8058-65. DOI: 10.1158/0008-5472.CAN-08-0153. View

19.

Lapointe R, Royal R, Reeves M, Altomare I, Robbins P, Hwu P . Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100. J Immunol. 2001; 167(8):4758-64. DOI: 10.4049/jimmunol.167.8.4758. View

20.

Eikawa S, Kakimi K, Isobe M, Kuzushima K, Luescher I, Ohue Y . Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide. Int J Cancer. 2012; 132(2):345-54. DOI: 10.1002/ijc.27682. View